26.21

1.31% 0.34

After Hours: 26.21

Maze Therapeutics Inc (MAZE)

Overview News Price History Discussions Forecast

Maze Therapeutics Inc stock is traded at $26.21, with a volume of 273.27K. It is up +1.31% in the last 24 hours and down -5.07% over the past month. Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Previous Close:

$25.87

Open:

$25.77

24h Volume:

273.27K

Relative Volume:

0.50

Market Cap:

$1.46B

Revenue:

$2.50M

Net Income/Loss:

$-131.12M

P/E Ratio:

-9.2188

EPS:

-2.8431

Net Cash Flow:

$-112.73M

1W Performance:

-4.48%

1M Performance:

-5.07%

6M Performance:

-43.61%

1Y Performance:

+74.27%

1-Day Range:

$25.66

$26.49

1-Week Range:

$25.66

$27.44

52-Week Range:

$14.27

$53.65

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name

Maze Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(650) 850-5070

Address

171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO

Employee

141

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

MAZE's Discussions on Twitter

Compare MAZE vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MAZE Maze Therapeutics Inc	26.21	1.61B	2.50M	-131.12M	-112.73M	-2.8431
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Mar-10-26	Initiated	Mizuho	Outperform
Dec-04-25	Initiated	Wells Fargo	Overweight
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy
Jul-23-25	Initiated	H.C. Wainwright	Buy
Jul-08-25	Initiated	Wedbush	Outperform

View All

Maze Therapeutics Inc Stock (MAZE) Latest News

Aug 20, 2026

Maze (MAZE) Trading: Ends Lower by 4.18% at $28.50 in the Latest Session; Price Context: the $27.07 to $29.93 Range Remains in FocusMESA MA - vinanet.vn

Aug 20, 2026

Aug 19, 2026

Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine

Aug 19, 2026

Maze (MAZE) Price: Climbs 0.72% to $29.34 at the Close; Market Levels: Support at $27.87 and Resistance at $30.81 Frame the RangeVolume Oscillator - vinanet.vn

Aug 19, 2026

Trv Gp Iv LLC Invests $133.50 Billion in Maze Therapeutics, Inc. $MAZE - MarketBeat

Aug 19, 2026

Trv Gp V LLC Buys Shares of 950,800 Maze Therapeutics, Inc. $MAZE - MarketBeat

Aug 19, 2026

Aug 18, 2026

Alphabet Inc. Acquires New Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat

Aug 18, 2026

Aug 17, 2026

Maze Therapeutics Confirms MZE829 Data Readout for Late 2026 or Early 2027 - Minichart

Aug 17, 2026

Maze Therapeutics (MAZE) awards director 36,000 stock options - Stock Titan

Aug 17, 2026

Maze Therapeutics (MAZE) awards director 36K stock options - Stock Titan

Aug 17, 2026

Maze Therapeutics (NASDAQ: MAZE) director shows no stock or derivative holdings - Stock Titan

Aug 17, 2026

Maze Therapeutics (MAZE) director begins reporting with zero shares disclosed - Stock Titan

Aug 17, 2026

Maze Therapeutics names Paula Johnson, Sophie Kornowski to board of directors - Bitget

Aug 17, 2026

Aug 15, 2026

Maze Therapeutics (MAZE) Pulls Back 1.75% as Shares Consolidate Above Key SupportMomentum Factor - vinanet.vn

Aug 15, 2026

128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - MarketBeat

Aug 15, 2026

Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - MarketBeat

Aug 15, 2026

Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa

Aug 15, 2026

Maze Therapeutics president sells $445,620 in company stock - Investing.com

Aug 15, 2026

Aug 14, 2026

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - MarketBeat

Aug 14, 2026

Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan

Aug 14, 2026

Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - Moomoo

Aug 14, 2026

HC Wainwright Has Positive Estimate for MAZE Q3 Earnings - MarketBeat

Aug 14, 2026

Maze Therapeutics (MAZE) Edges Higher to $27.66 as Shares Trade Within Established RangeETH Profile - vinanet.vn

Aug 14, 2026

Aug 13, 2026

Maze Therapeutics adds two directors to board By Investing.com - Investing.com Australia

Aug 13, 2026

Maze Therapeutics adds two directors to board - Investing.com

Aug 13, 2026

Maze Therapeutics Announces Appointments to Its Board of Directors - The Manila Times

Aug 13, 2026

Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors - Quiver Quantitative

Aug 13, 2026

A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110 - Moomoo

Aug 13, 2026